Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 8, 2019
- Accepted in final form June 25, 2019
- First Published August 22, 2019.
Article Versions
- Previous version (August 22, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Nicholas Schwab, PhD*,
- Tilman Schneider-Hohendorf, PhD*,
- Béatrice Pignolet, PhD*,
- Florence Bucciarelli,
- Lise Scandella, MSc,
- Jonathan Ciron, MD,
- Damien Biotti, MD,
- Christine Lebrun-Frenay, MD,
- Guillaume Mathey, MD, MSc,
- Pierre Clavelou, MD, PhD,
- Jean Pelletier, MD, PhD,
- Patrick Ostkamp, MSc,
- Ingrid Meinl, MD,
- Susanne Windhagen, MD,
- Luisa Klotz, MD,
- Catharina C. Gross, PhD,
- Sven G. Meuth, MD, PhD,
- Florian Deisenhammer, MD,
- David Brassat, MD, PhD*,
- Heinz Wiendl, MD*;
- on behalf of the Best-MS Study Group
- Nicholas Schwab, PhD*,
NONE
NONE
(1) Biogen, travel expenses, (2) Novartis, speaking honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) DFG CRC128 B1, starting 2012 (2) University Muenster, IMF, starting 2011 (3) PML Consortium, starting 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tilman Schneider-Hohendorf, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Béatrice Pignolet, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) FP7 - EU programm - BEST-MS - 305477-2012
(1) Fondation ARSEP - AO2017
NONE
NONE
NONE
NONE
NONE
NONE
- Florence Bucciarelli,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)FP7 EU Program BEST-MS 3054772012
(1)Fondation ARSEP French MS society AO2017
NONE
NONE
NONE
NONE
NONE
NONE
- Lise Scandella, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Ciron, MD,
Serving on Merck scientific board Serving on Roche scientific board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Damien Biotti, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christine Lebrun-Frenay, MD,
serving on a scientific advisory board from Biogen, Novartis, Merck, Genzyme,Teva, Roche
NONE
Funding for travel or speaker honoraria from Biogen, Merck, Genzyme, Roche
Serving as editorial advisory board member for Revue Neurologique (Paris) Elsevier, Neurology and therapy.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
UT Southwestern, Dallas, TX. Clinical advisor and senior professor.
Franch MS Society (SFSEP) EDMUS (OFSEP Center) Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Guillaume Mathey, MD, MSc,
NONE
NONE
Travel to ECTRIMS and American Acdemy of Neurology, from Biogen, Novartis, Merck-Serono, Genzyme-Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre Clavelou, MD, PhD,
Novartis (non profit entity) Teva Pharma (non profit entity) Bayer (non profit entity) Biogen (non profit entity) Genzyme-Sanofi (non profit entity) Almirall (non profit entity) Roche (non profit entity)
NONE
Non profit entity, fund directly to department of neurology : Novartis, Teva Pharma, Biogen, Merck, Bayer, Genzyme-Sanofi, Actelion, Roche
Editorial Advisory Board : La lettre du neurologue (french, no financial compensation, since twelve years)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jean Pelletier, MD, PhD,
(1) BIOGEN IDEC : member of advisory board (2) NOVARTIS : member of advisory board (3) GENZYME : member of advisory board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
ARSEP: research grants Novartis: research grants
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Ostkamp, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ingrid Meinl, MD,
NONE
NONE
IM received travel expenses from MedDay and Roche Pharma
NONE
NONE
NONE
NONE
NONE
NONE
IM received compensation from Serono for participation in an advisory board
NONE
My husband received grant support from Novartis, Merck and Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My husband received honorarium from Roche, Biogen, Novartis and Bioeq
- Susanne Windhagen, MD,
NONE
NONE
Honoraria for speaking engagements from Bayer Vital, Biogen, Merck-Serono, Novartis Pharma and TEVA-Pharma.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD,
(1) Genzyme (2) Novartis (3) Biogen (4) Roche (5) Merck (6) Teva (7) Janssen (8) Santhera
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) Biogen, speaker honoraria and travel support (4) Roche, speaker honoraria and travel support (5) Genzyme, speaker honoraria and travel support (6) Teva, speaker honoraria and travel support (7) Janssen, speaker honoraria and travel support (8) Santhera, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen (3) Merck
(1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis ? implications for CNS autoimmunity A08, Project leader, 2016-2020 (2) (CRC) SFB 1009 ?Immune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences? A03, Sub-project Leader, 2012-2020 (3) CRC; ?The role of the nuclear receptor NR4A1 in acute ischemic stroke: pathophysiology, therapy evaluation and human translation';Sub-Project leader, 2018-2020 (4) Federal Ministry of Education and Research (BMBF) Competence Network Multiple Sklerose: ?Multi-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors in MS?, 3.1 Sub-project Leader, 2016-2020 (5) Interdisciplinary Centre for Clinical Research, M?nster (IZKF),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catharina C. Gross, PhD,
NONE
NONE
I received speaker honoraria and travel expenses for attending meetings from Biogen, Euroimmun, Genzyme, Mylan, Novartis Pharma GmbH, and Bayer Health Care.
Frontiers in Immunology, Review Editor, Since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EU Horizon 2020 ReSTORE German Research Foundation (DFG), GR3946/3-1, 01/2018- 12/2020 German Research Foundation (DFG), GR3946/2-1, 01/2013- 12/2015 German Research Foundation (DFG), SFB-CRC-TR 129,Project A09 07/2016-06/2020 BMBF grant Disease-Related Competence Network Multiple Sclerosis, Immune MS, KKNMS-030
The Interdisciplinary Center for Clinical Studies (IZKF) Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of M?nster, KL111421, 07/2014-06/2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD,
(1) German association for Multiple Sclerosis (2) German Society for Neurology (DGN)(3) Neurology Trust (4) Center for Clinical Studies (ZKS) (5) Max Planck Society
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
(1) PLoS One (editor) (2) DGNeurologie, founding member editorial board
(1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4 ? 1402) (3)
NONE
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
NONE
NONE
NONE
Research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
Research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
NONE
Research is funded by Else Kr?ner Fresenius Foundation, Hertie Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Deisenhammer, MD,
(1) Biogen, (2) Celgene, (3) Genzyme-Sanofi, (4) Merck, (5) Novartis Pharma, (6) Roche
NONE
(1) Biogen, (2) Celgene, (3) Genzyme-Sanofi, (4) Merck, (5) Novartis Pharma, (6) Roche
Multiple Sclerosis and Related Disorders, section editor, 2012 - ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen, (2) Genzyme-Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Brassat, MD, PhD*,
Chugai pharma
NONE
Biogen, Bayer, Novartis, sanofi, almirall, Merck, teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
FP7 305477-2012-ongoing and PHRC 2008-2012‐00590638: PI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD*;
(1) Bayer Healthcare (2) Biogen Idec (3) Sanofi- Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva
NONE
(1) Bayer Vital GmbH (2) Bayer Schering AG (3) Biogen (4) CSL Behring (5) EMD Serono (6) Fresenius Medical Care (7) Sanofi - Genzyme (8) Merck Serono (9) Omniamed (10) Novartis (11) Teva (12) GlaxoSmithKline (13) GW Pharmaceuticals
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Biogen (2) Merck Serono (3) Novartis (4) Omniamed (5) Roche (6) Sanofi-Genzyme
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi ? Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kr?ner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children?s Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of the Best-MS Study Group
- From the Department of Neurology with Institute of Translational Neurology (N.S., T.S.-H., P.O., L.K., C.C.G., S.G.M., H.W.), University of Münster, Münster, Germany; CRC-SEP—Neurosciences Department (B.P., F.B., L.S., J.C., D. Biotti, D. Brassat), CHU Toulouse, Toulouse, France; CPTP—INSERM U1043—CNRS U5282—Université Toulouse III (B.P., F.B., L.S., D. Brassat), Toulouse, France; APHM (C.L.-F.), Hôpital de la Timone, Pôle de Neurosciences Cliniques, Marseille, France; CHU of Nice (G.M.), Nice, France; CHU Montpied, Neurology, Clermont-Ferrand, France (P.C.); APHM (J.P.), Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, CRCSEP Marseille, France; Institute of Clinical Neuroimmunology (I.M.), Ludwig-Maximilians University, Munich, Germany; Department of Neurology (S.W.), Clinics Osnabrück, Osnabrück, Germany; and Department of Neurology (F.G.), Innsbruck Medical University, Innsbruck, Austria.
- Correspondence
Dr. Schwab nicholas.schwab{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
- Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
- Nicholas Schwab, Scientist, University of Muenster, (Muenster, Germany)
- Tilman Schneider-Hohendorf, Scientist, University of Muenster, (Muenster, Germany)
- Béatrice Pignolet, Scientist, University of Toulouse (Toulouse, France)
- David Brassat, Neurologist, University of Toulouse (Toulouse, France)
- Heinz Wiendl, Neurologist, University of Muenster (Muenster, Germany)
Submitted October 25, 2019 - Reader response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
- Bastian Tugemann, Mathematician, Munich, Germany
Submitted October 15, 2019
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosingLana Zhovtis Ryerson, John Foley, Ih Chang et al.Neurology, September 12, 2019 -
Article
Natalizumab-induced POU2AF1/Spi-B upregulationA possible route for PML developmentMaria Meira, Claudia Sievers, Francine Hoffmann et al.Neurology - Neuroimmunology Neuroinflammation, March 31, 2016 -
Views & Reviews
Natalizumab-associated PMLChallenges with incidence, resulting risk, and risk stratificationNicholas Schwab, Tilman Schneider-Hohendorf, Nico Melzer et al.Neurology, February 22, 2017 -
Article
The natalizumab wearing-off effectEnd of natalizumab cycle, recurrence of MS symptomsZoé L.E. van Kempen, Djoeke Doesburg, Iris Dekker et al.Neurology, September 24, 2019